Stockreport

HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

HilleVax, Inc.  (HLVX) 
PDF $189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is exploring the potential for continued development of its noro [Read more]